ASCO Genitourinary Cancers Symposium 2025 (Videos + Slides + Posters)

Kosj Yamoah, MD, PhD—Chair
H. Lee Moffitt Cancer Center and Research Institute

Channing Judith Paller, MD—Chair
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Peter Hoskin, MD, FRCP, FRCR
Welcome of the Day

ABSTRACT 308: Gene signature predictor of dose-response to prostate radiation: Validation of PORTOS in phase III trials.
First Author: Shuang Zhao, MD

ABSTRACT 309: Radical prostatectomy (RP) versus radiotherapy (RT) in high-risk prostate cancer (HR-PCa): Emulated randomized comparison with individual patient data (IPD) from two phase III randomized trials (RCTs).
First Author: Soumyajit Roy, MBBS

Edwin Posadas, MD, FACP
Cedars-Sinai Medical Center
Discussion

ABSTRACT LBA18: Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line treatment in unselected patients with metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 TALAPRO-2 trial.
First Author: Neeraj Agarwal, MD, FASCO

ABSTRACT 20: Which patients with metastatic hormone-sensitive prostate cancer (mHSPC) benefit more from androgen receptor pathway inhibitors (ARPIs)? STOPCAP meta-analyses of individual participant data (IPD).
First Author: David John Fisher, MSc

Tanya B. Dorff, MD
City of Hope Comprehensive Cancer Center
Discussion
Panel Question and Answer

Angela Y Jia, MD, PhD—Chair
University Hospitals Seidman Cancer Center and Case Western Reserve University

Devaki Shilpa Surasi, MBBS—Chair
University of Texas at MD Anderson Cancer Center
PSMA-Based Therapy in Advanced Disease: Touching on Combination Sequencing

William Kevin Kelly, DO
Thomas Jefferson University Hospital
Beyond PSMA-Targeted Agents for Advanced Disease

Danny Mena Cortes
Nuclear Medicine World
Seeing Is Believing: Radiographic Criteria to Assess Response

ABSTRACT 17: Overall survival and quality of life with [¹⁷⁷Lu] Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in poor-risk, metastatic, castration-resistant prostate cancer in ENZA-p (ANZUP 1901).
First Author: Louise Emmett, MD, FRACP, MBChB

ABSTRACT 16: Association of baseline and on-treatment ctDNA fraction with clinical outcomes in patients with mCRPC in the PSMAfore study of ¹⁷⁷Lu-PSMA-617.
First Author: Johann S. De Bono, MD, PhD, MB, FRCP

Panel Question and Answer

View the networking faculty list here

Michael Cookson, MD, MMHC, FACS—Chair
University of Oklahoma College of Medicine

Barbara Jereczek-Fossa, MD—Chair
IEO European Institute of Oncology IRCCS

Michael Cookson, MD, MMHC, FACS
University of Oklahoma College of Medicine
Recurrence After Radiation Therapy: Evaluation, Management, and Outcomes

Heather H. Cheng, MD, PhD
University of Washington
Medical Oncology

Juanita Crook, FRCPC
The University of British Columbia
Radiation Oncology

Thomas Polascik, MD
Duke University Division of Urologic Surgery
Urology (Ablative Focal)

Ashley Ross, MD, PhD
Northwestern University Feinberg School of Medicine
Urology (Salvage Surgery)

Alicia K. Morgans, MD, MPH, FASCO
Dana-Farber Cancer Institute
The Impact of Salvage Therapies: Functional Outcomes and Quality of Life

Panel Question and Answer

Peter Hoskin, MD, FRCP, FRCR – Chair
Mount Vernon Cancer Centre, University College London, and University of Manchester
Introduction of Dr. Dahut

William L. Dahut, MD
American Cancer Society
Creative Innovation: Driving Science to Improve Patient-Centered Care

Question and Answer

Karen E. Hoffman, MD, MHSc, MPH—Chair
The University of Texas MD Anderson Cancer Center

Nicholas David James—Chair
Institute of Cancer Research, The Royal Marsden Hospital NHS Foundation Trust

ABSTRACT 15: World-wide oligometastatic prostate cancer (omPC) meta-analysis leveraging individual patient data (IPD) from randomized trials (WOLVERINE): An analysis from the X-MET collaboration.
First Author: Chad Tang, MD, BS, MS

Kenneth L. Gage, MD, PhD
H. Lee Moffitt Cancer Center and Research Institute
Radiology

Brandon A. Mahal, MD
University of Miami
Radiation Oncology

Kasmintan A. Schrader, PhD, MBBS
BC Cancer
Genetics

Sandy Srinivas, MD
Stanford School of Medicine
Medical Oncology

Panel Question and Answer

Marjory Jolicoeur, MD, PhD, FRCPC—Chair
Hôpital Charles-LeMoyne

ABSTRACT 310: Impact of testosterone recovery after androgen deprivation therapy on overall survival in patients with high-risk prostate cancer: Long-term data from a phase III trial. – 5 minutes
First Author: Abdenour Nabid, MD

ABSTRACT 311: Gut health and prostate cancer: The influence of a specific phytochemical-rich food capsule plus or minus a probiotic/prebiotic blend on symptoms and progression—A randomised, double-blind placebo-controlled trial. – 5 minutes
First Author: Robert J. Thomas, MD

ABSTRACT 312: A high omega-3, low omega-6 diet with fish oil for men with prostate cancer on active surveillance: The CAPFISH-3 randomized clinical trial. – 5 minutes
First Author: William Aronson, MD

ABSTRACT 21: Transdermal oestradiol (tE2) patches as androgen deprivation therapy (ADT): Efficacy and safety of combining with androgen receptor pathway inhibitors (ARPIs) in metastatic (M1) prostate cancer—Randomised comparison from the STAMPEDE trial platform. – 5 minutes
First Author: Nicholas David James, PhD, FRCP, MBBS

ABSTRACT 22: Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration resistant prostate cancer: A randomized phase II trial (GROUQ-PCS 9). – 5 minutes
First Author: Tamim Niazi, MD

ABSTRACT LBA138: Mevrometostat (PF-06821497), an enhancer of zeste homolog 2 (EZH2) inhibitor, in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC): A randomized dose-expansion study. – 5 minutes
First Author: Michael Thomas Schweizer, MD

Panel Question and Answer

Marjory Jolicoeur, MD, PhD, FRCPC
Hôpital Charles-LeMoyne
Poster Walk Leader

Channing Judith Paller, MD
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Poster Walk Leader

Elizabeth A. Guancial, MD—Chair
Florida Cancer Specialists & Research Institute

Nicholas I. Simon, MD, MSc—Chair
National Cancer Institute

Andrea B Apolo, MD
Welcome of the Day

ABSTRACT 658: Adjuvant nivolumab (NIVO) vs placebo (PBO) for high-risk muscle-invasive urothelial carcinoma (MIUC): Additional efficacy outcomes including overall survival (OS) in patients (pts) with muscle-invasive bladder cancer (MIBC) from CheckMate 274.
First Author: Matthew I. Milowsky, MD, FASCO

ABSTRACT 659: Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response (pCR) on long-term outcomes from NIAGARA. – 10 minutes
First Author: Matthew D. Galsky, MD, FASCO

Elizabeth R. Plimack, MD, FASCO, MS
Fox Chase Cancer Center, Temple Health
Discussion

ABSTRACT 661: Safety and efficacy of neoadjuvant immunotherapy with durvalumab (MEDI 4736) in combination with neoadjuvant chemotherapy (gemcitabine/cisplatin or carboplatin) in patients with operable high-risk upper tract urothelial carcinoma. – 10 minutes
First Author: Nadine Houede, MD

ABSTRACT 665: Neoadjuvant treatment with disitamab vedotin plus perioperative toripalimab in patients with muscle-invasive bladder cancer (MIBC) with HER2 expression: Updated efficacy and safety results from the phase II RC48-C017 trial. – 10 minutes
First Author: Xinan Sheng, MD

Scot Anthony Niglio, MD, MS
National Institutes of Health Division of Occupational Health and Safety
Discussion

Panel Question and Answer

Brian Christopher Baumann, MD—Chair
Springfield Clinic

Bogdana Schmidt, MD, MPH—Chair
University of Utah
The Changing World of Non-Muscle Invasive Bladder Cancer

Case Presentation

Girish S. Kulkarni, MD, PhD
Department of Surgical Oncology, Princess Margaret Cancer Center, University Health Network
Urology

Mark Tyson, MPH
Mayo Clinic Arizona
Urology

Tracy L Rose, MD
University of North Carolina at Chapel Hill
Medical Oncology

Panel Question and Answer

Aditya Bagrodia, MD—Chair
University of California, San Diego Health

Anja Lorch, MD—Chair
Universitätsspital Zürich

Nabil Adra, MD
Indiana University Health Melvin and Bren Simon Comprehensive Cancer Center
High-Dose Chemotherapy in Testicular Cancer: Current Evidence and Clinical Indications 

Axel Heidenreich, MD
University Hospital of Cologne
Primary Retroperitoneal Lymph Node Dissection in Stage II Seminoma: Management Strategies and Current Controversies

Darren R. Feldman, MD
Memorial Sloan Kettering Cancer Center
Landscape of New Trials and Targets in Refractory Germ Cell Tumors 

Panel Question and Answer 

Kent William Mouw, MD, PhD—Chair
Dana-Farber Cancer Institute, Brigham and Women’s Hospital

Benjamin Garmezy, MD—Chair
Sarah Cannon Research Institute

Di Maria Jiang, MD, MSc, FRCPC
Princess Margaret Hospital, University Health Network
Targeting Bladder Cancer With Antibody Drug Conjugates

Funda Meric-Bernstam, MD, FASCO
University of Texas MD Anderson Cancer Center
HER2 Antibody-Drug Conjugate Therapy: A New Frontier in Bladder Cancer

Daniel Castellano, MD
Servicio de Oncología Médica, Hospital Universitario 12 de Octubre
Overcoming Challenges of Antibody-Drug Conjugate Toxicity in Bladder Cancer

Terence W. Friedlander, MD
University of California, San Francisco Medical Center
Better Together? Exploring Novel Drug Combinations With Antibody-Drug Conjugates

ABSTRACT 657: Nectin-4 targeted ADC, SHR-A2102, in patients with advanced or metastatic urothelial carcinoma: A phase 1 study.
First Author: Bixia Tang, MD, PhD

Panel Question and Answer

Bernadett Szabados, MBBS—Chair
Barts Cancer Centre

Joaquim Bellmunt, MD—Chair
Dana-Farber Cancer Institute

Roger Li, MD
H. Lee Moffitt Cancer Center and Research Institute
Capturing What You Cannot See: How Can ctDNA Be Used to Improve Clinical Staging for Upper Tract Disease?

Alexander William Wyatt, PhD
Vancouver Prostate Centre, University of British Columbia
Evolution of Ctdna Detection with Next Generation Technology

Nimira S. Alimohamed, FRCPC
Arthur Child Comprehensive Cancer Centre, University of Calgary
Potential Impact of ctDNA on Perioperative Management of Muscle-Invasive Bladder Cancer

Gillian Vandekerkhove, PhD, MSc
Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia
Beneath the Surface: Unleashing the Potential of Ctdna across the Spectrum of Urothelial Carcinoma

Panel Question and Answer

Katie S. Murray, DO, FACS, MS—Chair
Department of Urology, NYU Langone Health

ABSTRACT 662: A first-in-human phase 1 study of LY3866288 (LOXO-435), a potent, highly isoform-selective FGFR3 inhibitor (FGFR3i) in advanced solid tumors with FGFR3 alterations: Initial results from FORAGER-1.
First Author: Gopa Iyer, MD

ABSTRACT 663: Datopotamab deruxtecan (Dato-DXd) in locally advanced/metastatic urothelial cancer: Updated results from the phase 1 TROPIONPanTumor01 study.
First Author: Funda Meric-Bernstam, MD, FASCO

ABSTRACT 664: EV-302: Updated analysis from the phase 3 global study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC).
First Author: Thomas Powles, MD, PhD, FCRP

ABSTRACT 666: Clinically advanced urothelial bladder cancer (CAUBC) in young onset bladder cancer (YOUC) patients: A genomic landscape study.
First Author: Alina Basnet, MD, MBBS

ABSTRACT 667: A phase 1/2 trial of durvalumab plus intravesical gemcitabine and docetaxel in BCG-unresponsive non-muscle invasive bladder cancer patients (HCRN GU16-243: ADAPT-BLADDER Cohort 4).
First Author: Noah M. Hahn, MD

ABSTRACT 815: A phase 2 trial of risk enabled therapy after neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer (RETAIN-2).
First Author: Pooja Ghatalia, MD

Panel Question and Answer

Elias Chandran, FRACP, MBBS
National Cancer Institute
Poster Walk Leader

Armine Smith, MD
Johns Hopkins University School of Medicine
Poster Walk Leader

Arpita Desai, MD—Chair
University of California, San Francisco

Daniel Shapiro—Chair
University of Wisconsin-Madison

Todd Matthew Morgan, MD
Welcome of the Day

ABSTRACT 438: Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC): Final results of COSMIC-313.
First Author: Laurence Albiges, MD, PhD

ABSTRACT 439: Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Final follow-up results from the CheckMate 9ER trial.
First Author: Robert J. Motzer, MD

ABSTRACT 440: KEYMAKER-U03 Substudy 03B: Pembrolizumab (pembro) and targeted therapy combinations for advanced clear cell renal cell carcinoma (ccRCC).
First Author: Katy Beckermann, MD, PhD

Tian Zhang, MD, MHS
UT Southwestern University
Discussion

ABSTRACT 618: Prospective COTRIMS (Cologne trial of retroperitoneal lymphadectomy in metastatic seminoma) trial: Final results.
First Author: Axel Heidenreich, MD

Clint Cary, MD, MBA, MPH
Indiana University Simon Comprehensive Cancer Center
Discussion

Panel Question and Answer

Shuchi Gulati, MD, MS, FACP—Chair
University of California, Davis Comprehensive Cancer Center

Axel Bex, MD, PhD—Chair
Royal Free London NHS Foundation Trust

ABSTRACT 437: Evaluation of circulating kidney injury marker-1 (KIM-1) as a prognostic and predictive biomarker in advanced renal cell carcinoma (aRCC): Post-hoc analysis of CheckMate 214.
First Author: Wenxin Xu, MD

Simpa Samuel Salami, MD, MPH
University of Michigan
Biomarkers in Renal Cell Carcinoma: Dead End or Turning Point?

Samra Turajlic, MD, PhD
The Francis Crick Institute
The Future of Biomarkers in Renal Cell Carcinoma

Laurence Albiges, MD, PhD
Gustave Roussy, Université Paris Saclay
Adjuvant Therapy in Renal Cell Cancer: A Practical Guide

Panel Question and Answer

View the networking faculty list here

Brittney Cotta, MD
University of Texas MD Anderson Cancer Center
Poster Walk Leader

Shuchi Gulati, MD, FACP, MS
UC Davis Comprehensive Cancer Center
Poster Walk Leader

Brittney Cotta, MD—Chair
University of Texas MD Anderson Cancer Center

ABSTRACT 441: Casdatifan (Cas) monotherapy in patients (pts) with previously treated clear cell renal cell carcinoma (ccRCC): Safety, efficacy and subgroup analysis across multiple doses from ARC-20, a phase 1 open-label study.
First Author: Toni K. Choueiri, MD, FASCO

ABSTRACT 442: Racial disparities in renal cell carcinoma histology and outcomes: Insights from the French Kidney Cancer Research Network (UroCCR-191).
First Author: Xiaofan Lu, PhD

ABSTRACT 443: Lenvatinib plus tislelizumab as first-line therapy for advanced fumarate hydratase-deficient renal cell carcinoma: A single-center, single-arm, phase II study.
First Author: Wen Kong, PhD

ABSTRACT 444: Final overall survival and new ctDNA analysis in MET-driven advanced papillary renal cancer (CALYPSO).
First Author: Francesca Jackson-Spence, MBChB

ABSTRACT 1: EPIC-A: Phase II trial of cemiplimab plus standard of care chemotherapy followed by maintenance cemiplimab in locally advanced or metastatic penile carcinoma.
First Author: Amit Bahl, MD, FRCP, FRCR

Panel Question and Answer

Leslie K. Ballas, MD—Chair
Cedars-Sinai Medical Center

Kathryn Hacker Gessner, MD, PhD—Chair
UNC School of Medicine

Maria T. Bourlon, MD, MSc, FASCO
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
Medical Oncology

Matthew T Campbell, MD, MS
The University of Texas MD Anderson Cancer Center
Medical Oncology

Raquibul Hannan, MD, PhD
University of Texas Southwestern Medical Center
Radiation Oncology

Viraj A. Master, MD, PhD
Emory School of Medicine
Urology

Panel Question and Answer